Evidence map›Paper›PMID 42306048›Full record

ArticleOpen life sciences2026

Irofulven and RSL3 synergistically target ferroptosis-related gene PTGR1 to treat head and neck squamous cell carcinoma.

Xiyuan Li, Lu Lu, Shuyao Yang, Yinglin Su, Chenfei Liu, Jingxia Xu, Lezong Chen, Chunlei Dai, Xumiao Zhang, Zhenzhen Chou and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiyuan LiDepartment of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Lu LuDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Shuyao YangNanyang Second General Hospital, Nanyang, 473000, Henan, China.
Yinglin SuDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Chenfei LiuDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.ORCID https://orcid.org/0009-0003-2323-6892
Jingxia XuDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Lezong ChenDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Chunlei DaiDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Xumiao ZhangDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Zhenzhen ChouDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Mingyuan DuDepartment of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Qiaohong LinDepartment of Thyroid Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.ORCID https://orcid.org/0009-0001-7591-5032
Jian MengDepartment of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Shiting ZhangDepartment of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Xiao ZhangKey Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of TCM, Nanchang, 330004, China.
Yuanbin SongDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Ming SongDepartment of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.ORCID https://orcid.org/0000-0001-7495-5895

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is an aggressive form of cancer characterized by significant fatality rates and unfavorable clinical outcomes. Ferroptosis serves as a crucial mechanism in controlling oncogenesis and tumor growth. However, the strategy targeting ferroptosis-related gene to predict and treat HNSCC is still not clear. The study was designed to assess the potential of ferroptosis as a biomarker and therapeutic target in HNSCC. A prognostic model based on ferroptosis-related genes was constructed using least absolute shrinkage and selection operator (LASSO). Multi-omic analysis revealed that the model was closely related to DNA methylation, DNA mutation and immune infiltration. HNSCC classification and the risk score in each classification were identified by analyzing single-cell RNA-sequencing (scRNA-seq) data. The results demonstrated that the risk score in malignant tumor classification is the highest, which is relative to the progression of HNSCC. Furthermore, through CellMiner database, we found the small molecular drug irofulven could target the risk score-related gene prostaglandin reductase 1 (PTGR1), which could inhibit the ferroptosis levels in HNSCC. Importantly, irofulven and ferroptosis inducer RSL3 exerted significant synergistic effects on HNSCC

Indexed as

ferroptosisHNSCCirofulvenPTGR1scRNA-seq

Identifiers

PMID42306048
PMCPMC13267736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.